Biologic agents in osteoarthritis: hopes and disappointments
Top Cited Papers
- 2 April 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Rheumatology
- Vol. 9 (7), 400-410
- https://doi.org/10.1038/nrrheum.2013.44
Abstract
New treatment options are needed for osteoarthritis (OA) to slow down the structural progression of the disease; current therapies mostly target pain and function with minimal effectiveness. OA results from an imbalance between catabolic and anabolic factors, and biologic agents either target specific catabolic proinflammatory mediators, such as cytokines, nitric oxide synthesis, or affect anabolism more generally. Biologic agents have dramatic effects in other rheumatic inflammatory diseases such as rheumatoid arthritis; they were hoped to have similar effects in the treatment of OA. In this Review, we will discuss the three main types of cytokine blockers used in knee and hand OA, which target β-nerve growth factor (β-NGF), IL-1β or TNF. We will also discuss inhibitors of nitrogen oxide production and the use of growth factors to treat OA. Among the targeted agents, anti-β-NGF therapy has shown promising results, although cases of rapid destructive arthropathy caution against its widespread use. The future of therapies targeting cytokines, nitrogen oxide synthesis and growth factors in OA is questionable, as results from clinical trials have been repeatedly negative. Strategies in OA therapy need to be reconsidered. New molecules emerging from preclinical data should focus on treating the early phase of the disease where damage may be reversible, and treatment should be modified to fit each patient.Keywords
This publication has 102 references indexed in Scilit:
- American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and kneeArthritis Care & Research, 2012
- Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modificationAnnals Of The Rheumatic Diseases, 2011
- A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the kneeArthritis Research & Therapy, 2011
- Synovial inflammation in patients undergoing arthroscopic meniscectomy: Molecular characterization and relationship to symptomsArthritis & Rheumatism, 2010
- Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritisBMC Musculoskeletal Disorders, 2010
- OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelinesOsteoarthritis and Cartilage, 2008
- High sensitivity C-reactive protein is associated with lower tibial cartilage volume but not lower patella cartilage volume in healthy women at mid-lifeArthritis Research & Therapy, 2008
- Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritisAnnals Of The Rheumatic Diseases, 2007
- EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)Annals Of The Rheumatic Diseases, 2007
- Obesity and osteoarthritis: more complex than predicted!Annals Of The Rheumatic Diseases, 2006